Yahoo · Sep 4, 2026
Perrigo (PRGO) Up 13.8% Since Last Earnings Report: Can It Continue?
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PR
NYSE · PRGO
Perrigo Company plc
Healthcare · Drug Manufacturers - Specialty & Generic
$14.92
Down-$0.34 (-2.28%)
Updated Sep 9, 2026, 1:30 AM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.85B
- P/E ratio
- -35.88
- Dividend yield
- 7.77%
- 52-week range
- $9.23 – $23.68
- Volume
- 2.2M
- Avg. volume
- 2.93M
Price performance
PRGO price history
1M range · 19 trading sessions · Daily adjusted prices
PRGO closed at $14.92 after 19 trading sessions, up 16.11% for the selected period.
- Last close
- $14.92
- Period change
- +16.11%
- Period low
- $12.69
- Period high
- $14.92
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $14.07 | $14.995 | $14.07 | $14.92 | 2.2M |
| Sep 3, 2026 | $14.71 | $14.80 | $14.095 | $14.27 | 1.87M |
| Sep 2, 2026 | $14.45 | $14.85 | $14.30 | $14.49 | 2.69M |
| Sep 1, 2026 | $14.52 | $14.90 | $14.315 | $14.43 | 3.69M |
| Aug 31, 2026 | $14.34 | $14.70 | $14.26 | $14.64 | 2.47M |
| Aug 28, 2026 | $14.09 | $14.565 | $14.002 | $14.48 | 2.6M |
| Aug 27, 2026 | $14.63 | $14.65 | $14.16 | $14.37 | 2.74M |
| Aug 26, 2026 | $14.505 | $14.795 | $14.38 | $14.76 | 2.6M |
| Aug 25, 2026 | $14.22 | $14.64 | $14.01 | $14.48 | 3.17M |
| Aug 24, 2026 | $14.18 | $14.35 | $14.04 | $14.27 | 2.11M |
| Aug 21, 2026 | $13.68 | $14.26 | $13.52 | $14.25 | 2.6M |
| Aug 20, 2026 | $13.71 | $13.945 | $13.49 | $13.70 | 2.37M |
| Aug 19, 2026 | $13.19 | $13.965 | $13.19 | $13.96 | 2.57M |
| Aug 18, 2026 | $12.96 | $13.19 | $12.80 | $12.97 | 2.18M |
| Aug 17, 2026 | $13.04 | $13.2123 | $12.81 | $12.82 | 2.14M |
| Aug 14, 2026 | $12.72 | $13.06 | $12.61 | $13.04 | 2.06M |
| Aug 13, 2026 | $12.80 | $13.075 | $12.505 | $12.83 | 2.53M |
| Aug 12, 2026 | $12.58 | $12.76 | $12.16 | $12.69 | 2.36M |
| Aug 11, 2026 | $12.53 | $12.945 | $12.42 | $12.85 | 2.27M |
Latest PRGO news
The latest Smart Investors Daily articles mentioning PRGO.
Stock researchCompany · Overview
PRGO research
Overview
Company profile and research snapshot.
Company profile
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $21.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 27, 2026 | Canaccord Genuity | Buy | — |
| Dec 15, 2025 | JP Morgan | Neutral | — |
| Nov 6, 2025 | Canaccord Genuity | Buy | — |
| Nov 6, 2025 | JP Morgan | Neutral | — |
| Oct 27, 2025 | Jefferies | Hold | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 27, 2026
Perrigo to Attend the Barclays Global Consumer Conference
Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Barclays Global Consumer Conference on Thursday, September 10th, 2026.
Yahoo · Aug 26, 2026
Should Value Investors Buy Perrigo (PRGO) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Benzinga · Aug 25, 2026
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector. Top analysts & recent news on PRGO, PFE, BMY.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
